SLC5A2 and Stroke: As mentioned previously, the meta-analyses of the CVOTs conducted in diabetic patients revealed that SGLT2 inhibitors as a class may have a neutral effect on fatal, non-fatal, and total stroke compared to placebos [20,21,22,41].